By Fineline Cube 
Eisai China Holdings (TYO: 4523) and Beckman Coulter Laboratory Systems (Suzhou) Co., Ltd. today signed a Letter of Intent (LOI) to deepen cooperation on the diagnosis and treatment of Alzheimer’s disease (AD) across mainland China, excluding Hong Kong, Macau, and Taiwan.
Core Collaboration Pillars
Expand Blood‑Based Alzheimer’s (BBA) Testing
— Integrate resources to broaden access to precise BBA testing, enabling more primary‑care institutions and patients to obtain timely diagnostics.
Evidence Generation for Early Diagnosis
— Conduct joint academic and scientific research to accumulate data supporting BBA testing in early AD, thereby informing clinical practice and policy.
Market Insight Sharing
— Exchange real‑time market intelligence to capture patient and healthcare system needs, laying groundwork for future joint ventures.
Future‑Oriented Initiatives
- Validation Studies – Co‑develop and execute validation studies for BBA technology.
- Patient Assistance Programs – Design Aβ‑testing assistance schemes to improve patient access and adherence.
- Screening Projects – Promote nationwide Alzheimer’s screening, advancing the disease‑prevention ecosystem through technology, patient care, and public health outreach.
Forward‑Looking Statements
The information herein contains forward‑looking statements regarding the LOI, prospective collaboration, and market developments. These carry risks and uncertainties that may cause actual results to differ materially.-Fineline Info & Tech